Dana-Farber's Gynecologic Oncology Program

Patient-centered care, clinical trials & translational research on gynecologic cancers @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-33

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Highlighting research from DFCI investigators, including Rebecca L. Porter, MD, PhD, and Panos A. Konstantinopoulos, MD, PhD, studying mirvetuximab soravtansine plus pembrolizumab in recurrent FOLR1/FRα-positive uterine serous carcinoma.

The phase 2 trial showed clinical activity and a manageable safety profile, supporting continued study of ADC-based combinations in gynecologic cancers.

#GynOnc #EndometrialCancer #CancerResearch #ClinicalTrials

https://t.co/27ed8nUBou

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Meet Dr. Rebecca Porter! She leads translational and clinical research efforts in ovarian cancer, working to develop new biomarkers and therapies while improving our understanding of treatment outcomes. #research #gynecologiconcology
Learn more: https://t.co/0OO2oiyWCO

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by @usnews
Learn more: https://t.co/Okzuh6wqBd

[Dana-Farber @DanaFarber]

Join leaders in radiation oncology, medical physics, healthcare operations, and cancer center administration for a multidisciplinary discussion on the emerging role of upright proton therapy. Learn more and register here: https://t.co/YLBBQpMZaK

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Following our introduction to Dr. Panos Konstantinopoulos, here’s a closer look at his presentation from ESGO in April, where he reviewed phase 2 data on ACR-368 in endometrial carcinoma. #GynecologicOncology #ESGO2026 #EndometrialCancer #Oncology #ClinicalResearch

https://t.co/hUMxPIzRQO

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Meet Dr. Panos Konstantinopoulos! He is the Director of the Mellen and Eisenson Family Center for BRCA and Related Genes and the Director of Translational Research in the Division of Gynecologic Oncology. Dr. K sees patients once a week and is actively involved in multiple gynecologic cancer clinical trials. Learn more about Dr. K here. @DanaFarberBRCA

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Promising progress in ovarian cancer research: Dana-Farber is studying new ways to tackle chemotherapy resistance and improve treatment options for patients. #cancerresearch #DanaFarber #research
#gynecologiccancer #ovariancancer #clinicaltrials
@DanaFarber @HarvardChanSPH

Read more: https://t.co/zbfafaaOYi #OvarianCancer #CancerResearch #ClinicalTrials

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

@DFCIGynOnc is leading a phase 2 study for recurrent ARID1A-mutated #endometrialcancer that involves PD-L1-targeting #avelumab with ATR-inhibitor M1774 (#tuvusertib). For info, call 877-338-7425 or visit: https://t.co/cgTnhFauAn

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

For more information on clinical trials and research in the Division of Gynecologic Oncology, please visit our website.
https://t.co/dJSZ7SJbXK

#GynOnc #CancerResearch #GynecologicOncology #DanaFarber #DFCIGynOnc #ClinicalTrials

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Clinical trial experts and patients at Dana-Farber share what kinds of resources may be available to support patients participating in clinical trials, including financial counseling, mental health support, social workers, and peer support.

https://t.co/Fm2xUEHllK

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Clinical trial experts and patients at Dana-Farber explain what it's like to be on a clinical trial, including informed consent, screening, your team, support for patients, and more.

https://t.co/pcvavpuUfa

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Patients and clinical trial experts at Dana-Farber explain what patients can expect when participating in a clinical trial and addressing common myths about clinical trials.

https://t.co/k6pDtHg9ab

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Research experts and patients at Dana-Farber explain what clinical trials are and how they contribute to improving care for patients with cancer.
https://t.co/eJhx6WqhnF

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

We proudly recognize Dr. Alexi Wright for participating in the Pan-Mass Challenge (PMC) this weekend. Her support of the PMC’s mission and dedication to advancing patient care are truly commendable. Congratulations, Dr. Wright!

#PMC #Panmasschallenge #DFCI #DanaFarber #GynOnc #GynecologicOncology

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Dr. Susana Campos reviews the most important gynecological oncology updates from ASCO 2026 with MedScape.

https://t.co/M1Rd9Xt26R

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

New research featuring Alexi A. Wright, MD, MPH, highlights REVITALIZE, a telehealth intervention designed to help adults with advanced ovarian cancer manage fatigue while receiving PARP inhibitors.

The study focuses on improving quality of life, fatigue-related outcomes, and treatment adherence.

Read more here: https://t.co/fpjpf229Ee

#DanaFarber #GynOnc #OvarianCancer #CancerResearch #REVITALIZE #telehealth #parpinhibitors

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Highlighting research co-authored by Alexi A. Wright, MD, MPH, on “days at home” after ovarian cancer surgery—a patient-centered outcome for older adults. The study found frailty was the strongest predictor of fewer days at home 1 year after surgery.

https://t.co/IDir1OcEb0

#OvarianCancer #GynOnc #frailty

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

Meet Dr. Alexi Wright, Associate Professor of Medicine at Harvard Medical School and medical oncologist at Dana-Farber Cancer Institute. Her work focuses on gynecologic oncology and health outcomes research to enhance patient-centered cancer care. #oncology #healthoutcomes
Learn more: https://t.co/BdXr4VJqxf

[Dana-Farber's Gynecologic Oncology Program @DFCIGynOnc]

New research featuring Alexi A. Wright, MD, MPH, highlights REVITALIZE, a telehealth intervention designed to help adults with advanced ovarian cancer manage fatigue while receiving PARP inhibitors.

The study focuses on improving quality of life, fatigue-related outcomes, and treatment adherence.

Read more here: https://t.co/fpjpf229Ee

#DanaFarber #GynOnc #OvarianCancer #CancerResearch #REVITALIZE #telehealth #parpinhibitors